Chronic kidney disease (CKD)- Epidemiology Forecast to 2030

May 2020 | 100 pages | ID: C5622C6BD312EN
DelveInsight

Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight’s ‘Chronic kidney disease (CKD)- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Chronic kidney disease in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

Chronic Kidney Disease (CKD) Understanding

Chronic kidney disease (CKD) is a type of kidney disease in which there is gradual loss of kidney function over a period of months to years. The initial symptoms include leg swelling, feeling tired, vomiting, loss of appetite, and confusion; complications in CKD involve anemia, bine disease, high blood pressure and increased risk of heart disease. Anemia is common and is especially prevalent in those requiring hemodialysis. It is multifactorial in cause, but includes increased inflammation, reduction in erythropoietin, and hyperuricemia leading to bone marrow suppression.

Chronic kidney disease Epidemiology Perspective by DelveInsight

The Chronic kidney disease (CKD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every seven major countries. The epidemiology data for Chronic kidney disease are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Chronic kidney disease Detailed Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Diagnosed Prevalent cases of CKD, Prevalent cases of CKD by stage, Prevalent cases of CKD by etiologies, Comorbidities associated with CKD, Dialysis dependency in CKD) scenario of Chronic kidney disease (CKD) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017–2030.

The DelveInsight CKD report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

• The report covers detailed overview of Chronic kidney disease explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Chronic Kidney Disease (CKD) Report and Model provide an overview of the risk factors and global trends of CKD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides the insight about the historical and forecasted patient pool of Chronic kidney disease in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
• The Report assesses the disease risk and burden and highlights the unmet needs of the disease
• The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report provides the segmentation of the disease epidemiology by Diagnosed Prevalent cases of CKD, Prevalent cases of CKD by stage, Prevalent cases of CKD by etiologies, Comorbidities associated with CKD, Dialysis dependency in CKD in 7MM

Report Highlights

• 11 Years Forecast
• 7MM Coverage
• Total Diagnosed Prevalent Cases of Chronic Kidney Disease
• Prevalent Cases according to segmentation: Prevalent cases of CKD by stage, Prevalent cases of CKD by etiologies, Comorbidities associated with CKD, Dialysis dependency in CKD

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Acute Lymphoblastic Leukemia?
• What are the key findings pertaining to the Chronic Kidney Disease epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017–2030)?
• What would be the total number of patients of Chronic Kidney Disease across the 7MM during the forecast period (2017–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017–2030)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017–2030)?
• What is the disease risk, burden and unmet needs of the Chronic Kidney Disease?
• What are the current available treatments of Chronic Kidney Disease?

Reasons to buy

The Chronic Kidney Disease Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Chronic Kidney Disease market
• Quantify patient populations in the global Chronic Kidney Disease market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Chronic Kidney Disease therapeutics in each of the markets covered
• Understand the magnitude of Chronic Kidney Disease population by its severity
• The Chronic Kidney Disease epidemiology report and model were written and developed by Masters and PhD level epidemiologists
• The Chronic Kidney Disease Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017–2030

The findings from the National Institute of Diabetes and Digestive and Kidney Diseases Health Information Center (NIDDK) suggests that the overall prevalence of CKD increased from 12 percent to 14 percent between 1988 and 1994 and from 1999 to 2004 but has remained relatively stable since 2004.

Similarly, the National Kidney Foundation states that CKD affects an estimated 37 million people in the U.S. (15% of the adult population; more than 1 in 7 adults) and approximately 90% of those with CKD do not even know they have it. Centers for Disease Control and Prevention (CDC) highlights that not all patients with kidney disease progress to kidney failure.

Contents

1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF CHRONIC KIDNEY DISEASE

3. SWOT ANALYSIS FOR CHRONIC KIDNEY DISEASE

4. DISEASE BACKGROUND AND OVERVIEW

4.1. Introduction
4.2. The KDIGO classification of CKD
4.3. Risk factors associated with CKD
4.4. Signs and symptoms
4.5. Pathophysiology
4.6. Complications
4.7. Disease Progression
4.8. Diagnosis, Screening and Prevention

5. EPIDEMIOLOGY AND PATIENT POPULATION

5.1. Key Findings
5.2. 7MM Total Prevalent Patient Population of Chronic Kidney Disease (CKD)
Country Wise-Epidemiology of CKD
5.3. The United States
  5.3.1. Assumptions and Rationale
  5.3.2. Diagnosed Prevalent cases of CKD
  5.3.3. Prevalent cases of CKD by stage
  5.3.4. Prevalent cases of CKD by etiologies in the United States
  5.3.5. Comorbidities associated with CKD in the United States
  5.3.6. Dialysis Dependency in CKD
5.4. EU-5
  5.4.1. Assumptions and Rationale
  5.4.2. Germany
    5.4.2.1. Diagnosed Prevalent cases of CKD in Germany
    5.4.2.2. Prevalent cases of CKD by stage in Germany
    5.4.2.3. Prevalent cases of CKD by etiologies in Germany
    5.4.2.4. Comorbidities associated with CKD in Germany
    5.4.2.5. Dialysis Dependency in CKD in Germany
  5.4.3. France
    5.4.3.1. Diagnosed Prevalent cases of CKD in France
    5.4.3.2. Prevalent cases of CKD by stage in France
    5.4.3.3. Prevalent cases of CKD by etiologies in France
    5.4.3.4. Comorbidities associated with CKD in France
    5.4.3.5. Dialysis Dependency in CKD in France
  5.4.4. Italy
    5.4.4.1. Diagnosed Prevalent cases of CKD in Italy
    5.4.4.2. Prevalent cases of CKD by stage in Italy
    5.4.4.3. Prevalent cases of CKD by etiologies in Italy
    5.4.4.4. Comorbidities associated with CKD in Italy
    5.4.4.5. Dialysis Dependency in CKD in Italy
  5.4.5. Spain
    5.4.5.1. Diagnosed Prevalent cases of CKD in Spain
    5.4.5.2. Prevalent cases of CKD by stage in Spain
    5.4.5.3. Prevalent cases of CKD by etiologies in Spain
    5.4.5.4. Comorbidities associated with CKD in Spain
    5.4.5.5. Dialysis Dependency in CKD in Spain
  5.4.6. The United Kingdom
    5.4.6.1. Diagnosed Prevalent cases of CKD in the United Kingdom
    5.4.6.2. Prevalent cases of CKD by stage in the United Kingdom
    5.4.6.3. Prevalent cases of CKD by etiologies in the United Kingdom
    5.4.6.4. Comorbidities associated with CKD in the United Kingdom
    5.4.6.5. Dialysis Dependency in CKD in the United Kingdom
  5.4.7. Japan
    5.4.7.1. Assumption and Rationale
    5.4.7.2. Diagnosed Prevalent cases of CKD in Japan
    5.4.7.3. Prevalent cases of CKD by stage in Japan
    5.4.7.4. Prevalent cases of CKD by etiologies in Japan
    5.4.7.5. Comorbidities associated with CKD in Japan
    5.4.7.6. Dialysis Dependency in CKD in Japan

6. TREATMENT AND MANAGEMENT

6.1. Biosimilars
6.2. Treatment guidelines for CKD
  6.2.1. Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline
  6.2.2. NICE Guidelines
6.3. Case Study
  6.3.1. Improving Outcomes for Patients with Chronic Kidney Disease
6.4. Patient Journey for CKD

7. UNMET NEEDS

8. APPENDIX

8.1. Report Methodology

9. DELVEINSIGHT CAPABILITIES

10. DISCLAIMER

11. ABOUT DELVEINSIGHT

List Of Tables

LIST OF TABLES

Table 1: Summary of Chronic Kidney Disease (CKD) Market, Epidemiology, and Key Events (2017–2030)

Table 2: Total Prevalent Patient Population of CKD in 7MM (2017–2030)

Table 3: Diagnosed Prevalent Cases of CKD in the United States (2017-2030)

Table 4: Prevalent Cases of CKD by stage in the United States (2017-2030)

Table 5: Prevalent cases of CKD by etiologies in the United States (2017-2030)

Table 6: Comorbidities associated with CKD in the United States (2017-2030)

Table 7: Dialysis dependency in the United States (2017-2030)

Table 8: Diagnosed Prevalent Cases of CKD in Germany (2017-2030)

Table 9: Prevalent Cases of CKD by stage in Germany (2017-2030)

Table 10: Prevalent cases of CKD by etiologies in Germany (2017-2030)

Table 11: Comorbidities associated with CKD in Germany (2017-2030)

Table 12: Dialysis dependency in Germany (2017-2030)

Table 13: Diagnosed Prevalent Cases of CKD in France (2017-2030)

Table 14: Prevalent Cases of CKD by stage in France (2017-2030)

Table 15: Prevalent cases of CKD by etiologies in France (2017-2030)

Table 16: Comorbidities associated with CKD in France (2017-2030)

Table 17: Dialysis dependency in France (2017-2030)

Table 18: Diagnosed Prevalent Cases of CKD in Italy (2017-2030)

Table 19: Prevalent Cases of CKD by stage in Italy (2017-2030)

Table 20: Prevalent cases of CKD by etiologies in Italy (2017-2030)

Table 21: Comorbidities associated with CKD in Italy (2017-2030)

Table 22: Dialysis dependency in Italy (2017-2030)

Table 23: Diagnosed Prevalent Cases of CKD in Spain (2017-2030)

Table 24: Prevalent Cases of CKD by stage in Spain (2017-2030)

Table 25: Prevalent cases of CKD by etiologies in Spain (2017-2030)

Table 26: Comorbidities associated with CKD in Spain (2017-2030)

Table 27: Dialysis dependency in Spain (2017-2030)

Table 28: Diagnosed Prevalent Cases of CKD in the United Kingdom (2017-2030)

Table 29: Prevalent Cases of CKD by stage in the United Kingdom (2017-2030)

Table 30: Prevalent cases of CKD by etiologies in the United Kingdom (2017-2030)

Table 31: Comorbidities associated with CKD in the United Kingdom (2017-2030)

Table 32: Dialysis dependency in the United Kingdom (2017-2030)

Table 33: Diagnosed Prevalent Cases of CKD in Japan (2017-2030)

Table 34: Prevalent Cases of CKD by stage in Japan (2017-2030)

Table 35: Prevalent cases of CKD by etiologies in Japan (2017-2030)

Table 36: Comorbidities associated with CKD in Japan (2017-2030)

Table 37: Dialysis dependency in Japan (2017-2030)

List Of Figures

LIST OF FIGURES

Figure 1: SWOT Analysis

Figure 2: Total Prevalent Patient Population of CKD in 7MM (2017–2030)

Figure 3: Diagnosed prevalent cases of CKD in the United States (2017-2030)

Figure 4: Prevalent Cases of CKD by stage in the United States (2017-2030)

Figure 5: Prevalent cases of CKD by etiologies in the United States (2017-2030)

Figure 6: Comorbidities associated with CKD in the United States (2017-2030)

Figure 7: Dialysis dependency in the United States (2017-2030)

Figure 8: Diagnosed prevalent cases of CKD in Germany (2017-2030)

Figure 9: Prevalent Cases of CKD by stage in Germany (2017-2030)

Figure 10: Prevalent cases of CKD by etiologies in the Germany (2017-2030)

Figure 11: Comorbidities associated with CKD Germany (2017-2030)

Figure 12: Dialysis dependency in Germany (2017-2030)

Figure 13: Diagnosed prevalent cases of CKD in the France (2017-2030)

Figure 14: Prevalent Cases of CKD by stage in France (2017-2030)

Figure15: Prevalent cases of CKD by etiologies in France (2017-2030)

Figure 16: Comorbidities associated with CKD in France (2017-2030)

Figure 17: Dialysis dependency in France (2017-2030)

Figure 18: Diagnosed prevalent cases of CKD in Italy (2017-2030)

Figure 19: Prevalent Cases of CKD by stage in Italy (2017-2030)

Figure 20: Prevalent cases of CKD by etiologies in Italy (2017-2030)

Figure 21: Comorbidities associated with CKD in Italy (2017-2030)

Figure 22: Dialysis dependency in Italy (2017-2030)

Figure 23: Diagnosed prevalent cases of CKD in Spain (2017-2030)

Figure 24: Prevalent Cases of CKD by stage in Spain (2017-2030)

Figure 25: Prevalent cases of CKD by etiologies in Spain (2017-2030)

Figure 26: Comorbidities associated with CKD in Spain (2017-2030)

Figure 27: Dialysis dependency in Spain (2017-2030)

Figure 28: Diagnosed prevalent cases of CKD in the United Kingdom (2017-2030)

Figure 29: Prevalent Cases of CKD by stage in the United Kingdom (2017-2030)

Figure 30: Prevalent cases of CKD by etiologies in the United Kingdom (2017-2030)

Figure 31: Comorbidities associated with CKD in the United Kingdom (2017-2030)

Figure 32: Dialysis dependency in the United Kingdom (2017-2030)

Figure 33: Diagnosed prevalent cases of CKD in Japan (2017-2030)

Figure 34: Prevalent Cases of CKD by stage in Japan (2017-2030)

Figure 35: Prevalent cases of CKD by etiologies in Japan (2017-2030)

Figure 36: Comorbidities associated with CKD in Japan (2017-2030)

Figure 37: Dialysis dependency in the Japan (2017-2030)

Figure 38: Steps in Manufacturing a Biologic Drug

Figure 39: Unmet Needs of Chronic Kidney Disease (CKD)